Jinpeng Pei

Title: Jinpeng Pei: Innovator in AXL-Targeting Antibodies

Introduction

Jinpeng Pei is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of targeted therapies for cancer treatment. His innovative work focuses on AXL-targeting antibodies, which have the potential to improve therapeutic outcomes for patients with tumors expressing high levels of AXL.

Latest Patents

Jinpeng Pei holds a patent for an AXL-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof. This patent discloses a new AXL-targeting monoclonal antibody and antibody-drug conjugate. The AXL antibody can effectively bind with purified human AXL protein and multiple AXL on tumor cell surfaces with high effectiveness and specificity. The humanized antibody exhibits high affinity and low immunogenicity, making it a promising candidate for cancer therapy. The AXL antibody-drug conjugate demonstrates remarkable performance against tumors with high AXL expression.

Career Highlights

Jinpeng Pei is affiliated with the Chinese Academy of Sciences, where he conducts his research and development activities. His work has garnered attention for its potential impact on cancer treatment, showcasing his dedication to advancing medical science.

Collaborations

Jinpeng Pei collaborates with notable colleagues, including Ke Yu and Jingkang Shen, who contribute to his research endeavors. Their combined expertise enhances the development of innovative solutions in the field of biotechnology.

Conclusion

Jinpeng Pei is a distinguished inventor whose work on AXL-targeting antibodies represents a significant advancement in cancer therapy. His contributions to the field are paving the way for more effective treatments for patients with high AXL expression tumors.